Trial reportThe Journal of infectious diseases2014
Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh.
Trial report in The Journal of infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes.The Cochrane database of systematic reviews · 2024Pooled it
- The age profile of respiratory syncytial virus burden in preschool children of low- and middle-income countries: A semi-parametric, meta-regression approach.PLoS medicine · 2023Pooled it
- Vaccines for the common cold.The Cochrane database of systematic reviews · 2022Pooled it
- Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial.Pediatrics · 2026Trial
- Dynamics of Respiratory Syncytial Virus Illness and Serology During Pregnancy and Infancy in the United States and South Africa.Open forum infectious diseases · 2025Trial
- Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women.The Journal of infectious diseases · 2022Trial
- A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.The Journal of infectious diseases · 2022Trial
- Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.The Lancet. Respiratory medicine · 2021Trial
- Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine.Human vaccines & immunotherapeutics · 2019Trial
- Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.The Journal of infectious diseases · 2018Trial
- Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Trial
- Clinical Presentation and Birth Outcomes Associated with Respiratory Syncytial Virus Infection in Pregnancy.PloS one · 2016Trial
- Budget impact analysis of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccination for preventing respiratory syncytial virus in Egyptian infants.Human vaccines & immunotherapeutics · 2026Article
- Review
- Long-acting monoclonal antibodies and the evolving landscape of infant respiratory syncytial virus prevention.Pediatric investigation · 2026Article
- Immune Mechanisms Underlying Neonatal Protection Following Maternal RSV Vaccination.International journal of molecular sciences · 2026Review
- Kinetics of antibodies and risk of respiratory syncytial virus infection: a longitudinal cohort in Taizhou City, eastern China.BMC medicine · 2026Article
- Maternal RSV immunization: clinical efficacy, immunological mechanisms and public health implications for preventing infant lower respiratory tract infection.Journal of health, population, and nutrition · 2026Review
- Budget impact of maternal vaccination with RSVpreF to protect privately insured infants in Dubai against respiratory syncytial virus.Human vaccines & immunotherapeutics · 2025Article
- Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
backgroundPneumonia is the leading cause of childhood mortality globally. Respiratory syncytial virus (RSV) is the most important viral cause of pneumonia. Maternal serum antibody protects infants from RSV disease. The objective of our study was to characterize RSV antibody levels in mother-infant pairs.
methodsSerial serum samples were collected from mother-infant pairs in Bangladesh from the third trimester of pregnancy to 72 weeks postpartum and tested using an RSV antibody microneutralization assay. Serologic infection was defined as a 4-fold increase in antibody titer. Maternal antibody half-life was calculated using infant antibody titers from birth to 20 weeks.
resultsThe ratio of infant cord blood to maternal serum RSV antibody titers in 149 mother-infant pairs was 1.01 (95% confidence interval [CI], .99-1.03). Maternal RSV antibody titers in the third trimester and at birth were strongly correlated (R = 0.68). Antibody half-life was 38 days (95% CI, 36-42 days). Higher cord blood RSV antibody titers were associated with a lower risk of serologic infection (P = .01) and maintenance of antibody titer above a potentially protective threshold (P < .001).
conclusionsEfficient transplacental transfer of RSV-specific antibody from mother to the fetus was documented in mother-infant pairs in Asia. Higher cord blood antibody titers were associated with protection from serologic infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.